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Abstract
Background: Older adults suffer from various chronic conditions which make them particularly vulnerable. The
proper management of multiple drug use is therefore crucial. The aim of our study was to describe drug
prescription and medication patterns in this population.
Methods: A cross-sectional study in Barcelona (Spain) using electronic health records from 50 primary healthcare
centres. Participants were aged 65 to 94 years, presenting multimorbidity (≥2 chronic diseases), and had been
prescribed at least 1 drug for 6 months or longer during 2009. We calculated the prevalence of prescribed drugs
and identified medication patterns using multiple correspondence analysis and k-means clustering. Analyses were
stratified by sex and age (65–79, 80–94 years).
Results: We studied 164,513 patients (66.8% women) prescribed a median of 4 drugs (interquartile range
[IQR] = 3–7) in the 65–79 age-group and 6 drugs (IQR = 4–8) in the 80–94 age-group. A minimum of 45.9% of
patients aged 65–79 years, and 61.8% of those aged 80–94 years, were prescribed 5 or more drugs. We
identified 6 medication patterns, a non-specific one and 5 encompassing 8 anatomical groups (alimentary
tract and metabolism, blood, cardiovascular, dermatological, musculo-skeletal, neurological, respiratory, and
sensory organ).
Conclusions: Drug prescription is widespread among the elderly. Six medication patterns were identified, 5 of
which were related to one or more anatomical group, with associations among drugs from different systems.
Overall, guidelines do not accurately reflect the situation of the elderly multimorbid, new strategies for
managing multiple drug uses are needed to optimize prescribing in these patients.
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Introduction
Worldwide, individuals are living longer [1] thanks to ad-
vances in medical research and care [2]. For instance, in
2016, 19% of the European population was aged 65 years or
older [3], a figure that is expected to reach 30% by 2060 [4].
Nevertheless, a longer life span is closely related to the like-
lihood of developing chronic disease [5] and 55–98% of
older adults suffer from multimorbidity [6]. Such patients
are more likely to require multiple drugs to achieve optimal
clinical (or disease) management [7, 8], indeed, a prescrip-
tion rate of over 80% for ≥5 drugs has been reported [9].
Multiple drug use in older adults, however, is associated
with overall worsening physical and psychological health as
a result of age-related changes in pharmacokinetics and
pharmacodynamics [10]. In addition, it has a potential in-
fluence on aspects of safety, including inappropriate pre-
scription, adverse drug reaction, risk of medication
interaction (drug-drug or drug-disease interaction), and ad-
herence [11, 12].
Due to ageing vulnerability, multiple drug use in the
multimorbid elderly is a main issue of concern for the
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public health system. Identifying which drugs are being
taken is crucial to define patients at risk. As a result, tools
need to be developed with the aim of decreasing prescrip-
tion errors, drugs interactions, adverse drug reactions, and
other consequences such as falls, hospitalization, and mor-
tality associated with multiple drug use [13, 14]. A recent
systematic review described clinical management oriented
to multimorbidity and polymedication. Its recommenda-
tions, however, were focused on the risks/benefits of each
drug individually rather than collectively [15]. To date, the
limited information available in the literature is mostly de-
scriptive [16] and methods regarding pharmaco-
epidemiology in multimorbidity have yet to be established.
Prescription groups and patterns could be of help in the
analysis of multiple drug use to create new strategies in the
management of complexity among multimorbid patients.
New techniques are being developed to create homoge-
neous patterns regarding the management of prescribed
drugs. For instance, exploratory factor analysis (EFA)
which is based on correlations between variables or fac-
tors, and cluster analysis (CA), a technique for grouping a
set of individuals in such a way that they are more similar
to each other than those in other groups [17]. EFA has re-
cently been reported to be useful for describing correl-
ation between variables, while CA carries out an in-depth
examination of the pattern for non-random associations
between the determinant variables of an individual [18]. In
recent years, EFA has been employed to define a number
of multimorbidity patterns [19–21], and some medication
ones [22]. Nonetheless, the statistical technique employed
should be taken into account. EFA correlates specific vari-
ables (e.g. diseases), but not all the variables of one unit
(e.g. patient), whilst CA could be helpful as the main start-
ing point to look for dissimilarities. Irrespective of the
methodology employed in these studies [23], there are
common biological systems encompassing multimorbidity
patterns: cardio-metabolic conditions, musculoskeletal
diseases, and mental health problems [24]. Serious dis-
eases and those with a greater prevalence according to
EFA/CA should thus be represented with the correspond-
ing medication.
We hypothesized that prescribed drugs could be grouped
using CA to identify clusters of patients with similar drugs
and consequently create medication patterns. The objective
of this study was to describe prescribed drugs and identify
medication patterns in multimorbid older adults.
Methods
Design, setting, and inclusion criteria
We conducted a cross-sectional analysis of electronic
health records (EHR) from the Information System for
Research in Primary Care (SIDIAP). This is a centralized
database that contains EHR from 2006 for all the pa-
tients who have attended primary health care centres
(PHCC) run by the public Catalan Health Institute [25,
26]. The study was performed in Barcelona (Spain) in
2009 with information from 50 PHCC. The participants
were aged 65 to 94 years, and the inclusion criteria were
a) to have attended a PHCC at least once during 2009;
b) to present multimorbidity, defined as the coexistence
of 2 or more chronic diseases [27]; and c) to have been
prescribed at least 1 drug for a period of 6 months or
longer during 2009 (see flow chart in Fig. 1).
The study protocol was approved by the Research Eth-
ics Committee at IDIAPJGol (Protocol no: P15/149). All
data were anonymized, and the confidentiality of the
EHR was maintained at all times in accordance with na-
tional and international law. As all data were anon-
ymized, no consent to individuals were required.
Variables
Prescription drugs were the main unit of measurement
and were coded as 1 (present) or 0 (absent). Drugs in
the SIDIAP database are classified using the Anatomical
Therapeutic Chemical (ATC) system (Additional file 1),
a measuring unit recommended by the World Health
Organization for drug studies. To classify the drugs in
this study, and facilitate subsequent analysis and inter-
pretation, we used the 4th level of the ATC system
which corresponds to chemical subgroups. Proton pump
inhibitors, for example, are coded as A02BC [28].
The other variables recorded for each participant were:
number of chronic diseases coded with the International
Classification of Primary Care second edition and se-
lected using the O’Halloran criteria [29], age (65–79
years vs 80–94 years), and sex (male vs female). Accord-
ing to the chronic diseases selected, chronic medication
was defined as the prescription of a drug for at least 6
continuous months during the period of study. Medica-
tion which did not fulfil this criterion was not analysed
as it was considered acute or not long-term. Neither
were supplements included as they are not financed by
the Spanish health system.
Statistical analysis
Data were extracted from the SIDIAP database after
authorization of the study [25]. All the authors had ac-
cess to the database. There were no missing values, as
sex, age, chronic diseases, and drugs were recorded for
all the sample.
Descriptive statistics were employed to summarize the
overall data. Categorical variables were expressed as fre-
quencies (percentage) and continuous variables as means
(standard deviation [SD]) or medians (interquartile range
[IQR]). Prevalence of prescription drugs was calculated
and medication patterns identified through 2 steps: 1)
multiple correspondence analysis (MCA), and 2) k-
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means clustering. All analyses were stratified by sex and
age.
Multiple correspondence analysis
MCA is a data analysis technique used to detect and rep-
resent underlying structures in sets of nominal categorical
data. It identifies groups with similar characteristics and
shows, in a multidimensional space, relationships between
dichotomous or categorical variables (in our case drug
prescriptions) that would be difficult to observe in a con-
tingency table [30, 31]. MCA also allows individuals to be
directly represented as points (coordinates) in a geometric
space through the transformation of original binary data
to continuous ones. The MCA was based on the indicator
matrix. The optimal number of dimensions extracted and
percentages of inertia were determined by means of a
scree plot.
K-means clustering
Using the geometric space created in the MCA, patients
were classified into clusters according to proximity cri-
teria by means of the k-means algorithm, and centers
obtained for each cluster. The optimal number of clus-
ters (k), which is the solution with the highest Calinski-
Harabaz index value, was assessed using criteria with
100 iterations. To assess internal cluster quality, cluster
stability of the optimal solution was computed using Jac-
card bootstrap values with 100 runs [17]. Highly stable
clusters should yield average Jaccard similarities of 0.85
and above.
Medication patterns
To describe the medication patterns across the clusters,
we used three criteria: a) the prevalence of prescribed
drugs in each cluster; b) the observed/expected (O/E) ra-
tios obtained by dividing the prevalence of a particular
drug in each cluster by the prevalence of the same pre-
scribed drug in the age and sex groups, considering
over-represented drugs when value ≥2; and c) exclusiv-
ity, defined as the proportion of individuals with a par-
ticular prescribed drug included in the cluster over the
total number of individuals with a particular prescribed
drug in the corresponding age and sex group, consider-
ing high exclusivity when value ≥50%.
Fig. 1 Flow chart
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Medication patterns were defined by considering drugs
with a prevalence ≥20% or an O/E ratio ≥ 2. To identify the
importance of each medication and, as a consequence, the
amount of medication included in a cluster, we employed
exclusivity. In order to facilitate the designation of a medi-
cation pattern we named the patterns considering medica-
tions belonging to the same ATC group with an exclusivity
value ≥50%, even when presenting a low prevalence. And
we also took into consideration to name the pattern those
drugs over-represented by O/E ratio ≥ 2. We then described
medications included in each cluster using three numbers
of characteristics: prevalent drugs (prevalence ≥20%), drugs
over-represented (O/E ratio ≥ 2) and exclusive drugs (exclu-
sivity ≥50%). But we considered only exclusive and over-
represented drugs to label the pattern.
In addition to mathematical validation, clinical criteria
based on previous literature [32–34] and clinical feed-
back from the research team (3 family physicians and 2
epidemiologists) were employed to evaluate the
consistency and significance of the final cluster solution.
The analyses were carried out using SPSS for Win-
dows, version 24 (SPSS Inc., Chicago, IL, USA) and R
version 3.4.2 (R Foundation for Statistical Computing,
Vienna, Austria).
Results
The sample was composed of 164,513 patients aged ≥65
years all of whom presented multimorbidity and had at
least 1 drug prescribed; 66.8% were women. The group
65–79 years had a mean age of 72.0 years (SD = 4.3) and
was prescribed a median of 4 (IQR = 3–7) drugs. The
group 80–94 years had a mean age of 84.1 years (SD =
3.4) and was prescribed a median of 6 (IQR: 4–8) drugs.
At least 45.9% of the 65–79 year and 61.8% of the 80–
94 year groups were prescribed 5 or more drugs. As ex-
pected, the use of 10 or more drugs was almost twice in
the 80–94 compared to the 65–79 year age group. The
number of prescribed drugs and chronic diseases did not
differ between sexes (Table 1). The 10 most widely pre-
scribed drugs across the sample belonged to 3 ATC sys-
tem groups: alimentary tract and metabolism (A),
nervous system (N), and cardiovascular system (C). Pro-
ton pump inhibitors and HMG CoA reductase inhibitors
were present in the top 3 most prescribed drugs in all
groups, with platelet aggregation inhibitors (excluding
heparin) in men and benzodiazepine derivatives (65–79
years) and anilides (80–94 years) for women (Table 2).
Characteristics of medication patterns
Six medication patterns for each age and sex group were
identified. All the groups had a non-specific pattern con-
sisting of highly prevalent drugs that were neither over-
represented nor exclusive. The other 5 patterns were
made up of drugs belonging to 1 or more anatomical
groups corresponding to: alimentary tract and metabol-
ism (A), blood and blood forming organs (B), cardiovascu-
lar system (C), dermatological (D), musculoskeletal system
(M), nervous system (N), respiratory system (R), and sen-
sory organs (S) (Table 3, Additional files 2, 3 and 4).
As an example, findings for women 65–79 years are rep-
resented in Table 3. Six medication patterns were identified,
numbered according to the weight of the sample implied
(descending order): non-specific (cluster 1), followed by ner-
vous system (cluster 2), musculo-skeletal + dermatological
(cluster 3), alimentary tract and metabolism (cluster 4), re-
spiratory system (cluster 5), and cardiovascular system
Table 1 Descriptive data, by sex and age groups, of the multimorbid patients (n = 164,513) aged 65–94 years attended in 2009 at
primary healthcare centres located in Barcelona
Women Men
65–79 years 80–94 years 65–79 years 80–94 years
Participants n (%) 78,008 (47.4) 31,848 (19.4) 41,931 (25.5) 12,726 (7.7)
Number drugs n (%)
1–4 40,931 (52.5) 11,374 (35.7) 22,703 (54.1) 4868 (38.3)
5–9 31,500 (40.4) 16,460 (51.7) 16,339 (39.0) 6268 (49.3)
≥10 5577 (7.1) 4014 (12.6) 2889 (6.9) 1590 (12.5)
Median number of drugs (IQRa) 4 (3–7) 6 (4–8) 4 (2–6) 5 (3–8)
Number of chronic diseases n (%)
2 2806 (3.6) 1125 (3.5) 1792 (4.3) 410 (3.2)
[3–5] 20,301 (26.0) 7689 (24.1) 12,484 (29.8) 3090 (24.3)
[6–9] 33,089 (42.4) 13,495 (42.4) 17,955 (42.8) 5562 (43.7)
≥10 21,812 (28.0) 9539 (30.0) 9700 (23.1) 3664 (28.8)
Median number of chronic diseases (IQRa) 7 (5–10) 8 (5–10) 7 (5–9) 7 (5–10)
IQRa Interquartile range
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(cluster 6). For each cluster, three subgroups of prescribed
drugs that encompassed the pattern were defined. Three
kinds of data were shown for every cluster. Using the ex-
ample of the musculo-skeletal and dermatological pattern
(cluster 3), we identified three different groups of drugs in
the pattern:
a) drugs with a high prevalence but not over- repre-
sented such as proton pump inhibitors (prevalence 66%,
O/E ratio 1.58, exclusivity 19%) and benzodiazepine de-
rivatives (prevalence 33%, O/E ratio 1.26, exclusivity
15%);
b) drugs with a high/low prevalence over-represented
with exclusivity < 50% such as anilides (prevalence 61%,
O/E ratio 2.57, exclusivity 31%) and other opioids (preva-
lence 10%, O/E ratio 3.25, exclusivity 40%);
c) drugs with a high/low prevalence over-represented
and with exclusivity ≥ 50% such as anti-inflammatory
preparations, non-steroids for topical use (prevalence
33%, O/E ratio 5.96, exclusivity 70%) and potent cortico-
steroids (group III) (prevalence 9%, O/E ratio 6.65, exclu-
sivity 81%) (Table 3).
It was observed that the non-specific pattern had the
greatest number of patients for all groups and was de-
fined by drugs that were neither prevalent nor over-
represented. With respect to the non-specific pattern, the
number of patients aged 65–79 years was higher than
those aged 80–94 years for both sexes. According to the
frequency of patients, the next patterns were: for women
65–79 years “nervous system” and “musculo-skeletal +
dermatological”, whilst for women 80–94 years they in-
cluded alimentary tract and metabolism as a drug group
implied in frequency; for men 65–79 years they were
“cardiovascular system” and “alimentary tract and me-
tabolism”, and for those 80–94 years was added the drug
group related to musculo-skeletal and nervous system
(Table 3, Additional files 2, 3 and 4).
Comparing patterns between sexes, women had four
patterns in both age groups which implied only one
over-represented anatomical system (alimentary tract
and metabolism, cardiovascular system, nervous sys-
tem, and respiratory system), in contrast to men who
had only two patterns implying one anatomical
Table 2 The ten most commonly prescribed drugs in 2009 for multimorbid patients (n = 164,513) aged 65–94 years, by sex and age
groups, attended at primary healthcare centres located in Barcelona
Women Men
ATC codea Drug name N % ATC codea Drug name N %
65–79 years A02BC Proton pump inhibitors 32,634 41.8 C10AA HMG CoA reductase inhibitors 18,188 43.4
C10AA HMG CoA reductase inhibitors 32,004 41.0 A02BC Proton pump inhibitors 15,170 36.2
N05BA Benzodiazepine derivatives 20,649 26.5 B01AC Platelet aggregation inhibitors excl. Heparin 13,872 33.1
N02BE Anilides 18,434 23.6 C09AA ACE inhibitors, plain 9748 23.2
B01AC Platelet aggregation
inhibitors excl. Heparin
15,338 19.7 G04CA Alpha-adrenoreceptor antagonists 7235 17.3
C09AA ACE inhibitors, plain 13,578 17.4 A10BA Biguanides 6306 15.0
M05BA Bisphosphonates 13,309 17.1 N05BA Benzodiazepine derivatives 6019 14.4
N06AB Selective serotonin reuptake inhibitors 11,522 14.8 C08CA Dihydropyridine derivatives 5996 14.3
C03AA Thiazides, plain 10,112 13.0 C07AB Beta blocking
agents, selective
5934 14.2
C09CA Angiotensin II antagonists, plain 9231 11.8 N02BE Anilides 5625 13.4
80–94 years A02BC Proton pump inhibitors 16,496 51.8 A02BC Proton pump inhibitors 5877 46.2
N02BE Anilides 11,370 35.7 B01AC Platelet aggregation inhibitors excl. Heparin 5641 44.3
C10AA HMG CoA reductase inhibitors 11,222 35.2 C10AA HMG CoA reductase inhibitors 4657 36.6
B01AC Platelet aggregation
inhibitors excl. Heparin
10,512 33.0 C09AA ACE inhibitors, plain 3235 25.4
N05BA Benzodiazepine derivatives 9633 30.2 N02BE Anilides 2638 20.7
C09AA ACE inhibitors, plain 7223 22.7 G04CA Alpha-adrenoreceptor antagonists 2601 20.4
C08CA Dihydropyridine derivatives 5283 16.6 N05BA Benzodiazepine derivatives 2313 18.2
C03CA Sulfonamides, plain 5265 16.5 C08CA Dihydropyridine derivatives 2260 17.8
N06AB Selective serotonin reuptake inhibitors 5258 16.5 C03CA Sulfonamides, plain 1930 15.2
C09CA Angiotensin II antagonists, plain 4502 14.1 C01DA Organic nitrates 1622 12.7
Codea: chemical subgroup, 4rt level, ATC code (Anatomical Therapeutic Chemical classification) from the World Health Organization (Additional file 1)
For more details, visit webside: https://www.whocc.no/atc/structure_and_principles/
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Table 3 Example of medication patterns across women 65–79 years attended in primary health centres in Barcelona during 2009
(N = 78,008)
Code& Drugs Preb O/E
ratioa
Exclus.
Cluster 1 n = 39,202 (50%)
Non-specific pattern C10AA HMG CoA reductase inhibitors 32% 0.78 39%
A02BC Proton pump inhibitors 21% 0.51 26%
Cluster 2 n = 14,604 (19%)
Nervous system pattern A02BC Proton pump inhibitors 70% 1.68 31%
N05BA Benzodiazepine derivatives 58% 2.18 41%
C10AA HMG CoA reductase inhibitors 56% 1.36 25%
N06AB Selective serotonin reuptake inhibitors 40% 2.71 51%
B01AC Platelet aggregation inhibitors excl. Heparin 35% 1.76 33%
M05BA Bisphosphonates 28% 1.62 30%
N02BE Anilides 26% 1.10 21%
N06AX Other antidepressants 14% 3.49 65%
N03AX Other antiepileptics 10% 3.16 59%
N05CD Benzodiazepine derivatives 9% 2.03 38%
A12AA Calcium 7% 2.58 48%
N06AA Non-selective monoamine reuptake inhibitors 7% 3.07 57%
C01DA Organic nitrates 7% 2.32 43%
N02AX Other opioids 6% 2.03 38%
A11CC Vitamin D and analogues 6% 2.97 56%
A06AD Osmotically acting laxatives 6% 2.04 38%
N03AE Benzodiazepine derivatives 4% 3.69 69%
C07AA Beta blocking agents, non-selective 4% 2.61 49%
H02AB Glucocorticoids 4% 2.71 51%
C10AX Other lipid modifying agents 4% 2.25 42%
N06DX Other anti-dementia drugs 3% 2.44 46%
A03FA Propulsive 3% 2.25 42%
Cluster 3 n = 9502 (12%)
“Musculo-skeletal system” and
“Dermatologicals” pattern
A02BC Proton pump inhibitors 66% 1.58 19%
N02BE Anilides 61% 2.57 31%
N05BA Benzodiazepine derivatives 33% 1.26 15%
M02AA Antiinflammatory preparations, non-steroids for tropical use 31% 5.96 73%
C10AA HMG CoA reductase inhibitors 30% 0.74 9%
M01AE Propionic acid derivatives 27% 4.30 52%
C05CA Bioflavonoids 19% 2.88 35%
M01AX Other antiinflammatory and antirheumatic agents, non-steroids 17% 2.84 35%
A02AD Combinations and complexes of aluminium, calcium and magnesium
compounds
15% 4.24 52%
M01AB Acetic acid derivatives and related substances 15% 5.17 63%
D01AC Imidazole and triazole derivatives 10% 5.93 72%
N02AX Other opioids 10% 3.25 40%
D07AC Corticosteroidas, potent (group III) 9% 6.65 81%
N02BB Pyrazolones 6% 5.30 65%
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Table 3 Example of medication patterns across women 65–79 years attended in primary health centres in Barcelona during 2009
(N = 78,008) (Continued)
Code& Drugs Preb O/E
ratioa
Exclus.
A06AD Osmotically acting laxatives 6% 2.13 26%
R05CB Mucolytics 5% 2.83 34%
R06AX Other antihistamines for systemic use 5% 3.34 41%
N07CA Antivertigo preparations 5% 2.26 28%
Cluster 4 n = 8745 (11%)
Alimentary tract and metabolism pattern C10AA HMG CoA reductase inhibitors 68% 1.67 19%
A10BA Biguanides 65% 5.86 66%
B01AC Platelet aggregation inhibitors excl. Heparin 61% 3.12 35%
A02BC Proton pump inhibitors 50% 1.19 13%
A10BB Sulfonylureas 37% 6.69 75%
C09AA ACE inhibitors, plain 30% 1.70 19%
C08CA Dihydropyridine derivatives 29% 2.68 30%
C07AB Beta blocking agents, selective 23% 2.18 24%
N02BE Anilides 22% 0.94 10%
A10AC Insulins and analogues for injection, intermediate-acting 10% 6.34 71%
C01DA Organic nitrates 9% 3.22 36%
A10AE Insulins and analogues for injection, long-acting 9% 6.04 68%
M04AA Preparations inhibiting uric acid production 9% 2.97 33%
C02CA Alpha-adrenoreceptor antagonists 7% 3.57 40%
C10AB Fibrates 7% 2.96 33%
A10AD Insulins and analogues for injection, intermediate- or long- acting
combined with fast- acting
7% 6.24 70%
G04CA Alpha-adrenoreceptor antagonists 4% 2.13 24%
C10AX Other lipid modifying agents 4% 2.36 26%
Cluster 5 n = 3275 (4%)
Respiratory system pattern R03AC Selective beta-2-adrenoreceptor agonists 72% 16.88 71%
A02BC Proton pump inhibitors 54% 1.30 5%
R03BB Anticholinergics 54% 18.86 79%
R03AK Adrenergics in combination with corticosteroids or other drugs, excl.
Anticholinergics
51% 11.87 50%
R03BA Glucocorticoids 40% 18.45 77%
C10AA HMG CoA reductase inhibitors 38% 0.94 4%
N02BE Anilides 32% 1.36 6%
N05BA Benzodiazepine derivatives 27% 1.01 4%
B01AC Platelet aggregation inhibitors excl. Heparin 23% 1.17 5%
C03CA Sulfonamides, plain 14% 2.11 9%
R05CB Mucolytics 11% 6.34 27%
R06AX Other antihistamines for systemic use 6% 3.79 16%
C08DB Benzothiazepine derivatives 5% 2.26 9%
H02AB Glucocorticoids 4% 3.07 13%
G04CA Alpha-adrenoreceptor antagonists 4% 2.02 8%
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system (cardiovascular and respiratory system). The
other patterns were formed by two or more anatom-
ical systems. The rest of the results are detailed in
Table 3 and Additional files 2, 3 and 4.
Comparing patterns between age groups, no significant
differences were observed for women with the exception of
additional drugs encompassing the non-specific pattern
(anilides, ACE inhibitors, benzodiazepine derivatives) (Table
3, Additional file 2). The men’s patterns, however, appeared
more complex: to the non-specific pattern were added two
drugs (platelet aggregation inhibitors excluding heparin and
proton pump inhibitors), and in the 80–94 age group the
patterns encompassed multiple anatomical groups includ-
ing a sensory organs pattern (Additional files 3 and 4).
Discussion
In this study, we present data regarding prescription
drugs in an urban population of elderly adults with mul-
timorbidity. Prescription rates were high, particularly in
the older subset of patients, probably due to the greater
burden of chronic disease. Proton pump inhibitors were
the most widely prescribed drug with cardiovascular and
neurological drugs representing the most frequently pre-
scribed groups. We defined 6 medication patterns which
provide information about the multiple drugs grouped
closely together in elderly patients. The pattern with the
most participants, non-specific, had up to 39% of the
age-sex sample included and was composed of drugs
corresponding to specific diseases (hypertension, lipid
disorder, depressive disorder (women)) and others re-
lated to the secondary prevention of cardiovascular/di-
gestive diseases (platelet aggregation inhibitors and
proton pump inhibitors). The rest of the medication pat-
terns could be linked to the multimorbidity ones defined
in a previous article performed in the same sample [35].
Comparison with published literature
Ageing is associated with functional decline, and the
prescription of multiple drugs tends to be highest in the
oldest segments of the population [36]. Just over half the
patients in our study had been prescribed 5 or more
drugs, rates of between 45.0 and 80.0% have been previ-
ously described based on primary care EHR [9, 37].
These results showed that the 10 most prescribed drugs
Table 3 Example of medication patterns across women 65–79 years attended in primary health centres in Barcelona during 2009
(N = 78,008) (Continued)
Code& Drugs Preb O/E
ratioa
Exclus.
Cluster 6 n = 2680 (3%)
Cardiovascular system pattern B01AA Vitamin K antagonists 78% 15.74 54%
C03CA Sulfonamides, plain 66% 10.05 35%
A02BC Proton pump inhibitors 58% 1.37 5%
C01AA Digitalis glycosides 53% 27.60 95%
C10AA HMG CoA reductase inhibitors 43% 1.06 4%
N02BE Anilides 32% 1.35 5%
N05BA Benzodiazepine derivatives 29% 1.11 4%
C09AA ACE inhibitors, plain 27% 1.56 5%
C07AB Beta blocking agents, selective 24% 2.25 8%
C09CA Angiotensin II antagonists, plain 23% 1.98 7%
A12BA Potassium 20% 16.35 56%
C03DA Aldosterone antagonists 19% 17.02 58%
C08DB Benzothiazepine derivatives 13% 6.07 21%
C07AG Alpha and beta blocking agents 12% 8.91 31%
M04AA Preparations inhibiting uric acid production 11% 3.73 13%
C01DA Organic nitrates 9% 3.26 11%
B03AA Iron bivalent, oral preparations 5% 3.60 12%
A10AE Insulins and analogues for injection, long-acting 3% 2.30 8%
A02BA H2 - receptor antagonists 3% 2.12 7%
Code&:Chemical subgroup, 4rt level, ATC code (Anatomical Therapeutic Chemical classification) from the World Health Organization
O/E ratioa: Observed/expected ratio
Preb: Prevalence
Exclus.: Exclusivity
Selected criteria: Prevalence ≥ 20 or Observed/Expected ratio ≥ 2
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were to treat metabolic, cardiovascular, and nervous sys-
tem disorders, in line with other reports for the elderly
[35, 38, 39]. As expected, considering that heart disease
is the leading cause of death in such populations [40],
cardiovascular drugs were the main group of prescribed
drugs. Looking more closely, proton pump inhibitors
were the most widely prescribed drug in our study, con-
trasting with findings on the prevalence of digestive tract
chronic diseases conducted in the same sample [35].
Off-label use of proton pump inhibitors could be related
to the prevention of adverse gastrointestinal effects, as
reported elsewhere [41]. In addition, a high prevalence
of lipid modifying (C10AA) agents and antithrombotic
drugs (B01AC) was probably linked to their use in the
primary and secondary prevention of thrombotic events.
We would like to point out that benzodiazepines, despite
their potentially adverse effects for older adults (e.g,
memory impairment, delirium, falls) [42, 43], were still
frequently prescribed in our population (from 14.4% in
men 65–79 years to 30.2% in women 80–94 years), with
a reported prevalence among the elderly from 10.0 to
41.6% [44, 45].
Six patterns per group defining user profiles with pre-
scribed drugs were obtained. We took into account pre-
scribed drugs, instead of consumed ones, because we
assumed patients followed what their doctors suggested.
As we studied patients with multimorbidity, we consid-
ered chronic drugs rather than supplements or acute
prescriptions. As a result, many of the defined patterns
seemed logical and in concordance with chronic disease
prevalence [35]. In addition, differences in intra- and
inter-patterns were represented defining prevalence, O/E
ratio, and exclusivity for each drug. The relevance of the
prescribed drug was thus represented by these three
parameters.
The non-specific pattern had the greatest number of
patients in all strata as no anatomical group was over-
represented. It could, therefore, be hypothesized that pa-
tients evolve to 5 specific patterns across time, that is to
say, the non-specific pattern could represent a pre-state
of a specific one. In addition, the fact that the number of
patients included in the non-specific pattern was lower
in the 80–94 than the 65–79 year group points to the
hypothesis that this pattern could be a pre-specific medi-
cation one. Nevertheless, longitudinal analyses should be
conducted to substantiate this issue. With respect to
specific patterns, the men’s appeared more complex than
women’s possibly because of the anatomical systems in-
volved and male smoking habits [46]. In concordance
with this difference, more men in the 65–79 year group
presented cardiovascular and respiratory patterns than
women who showed mostly neuromuscular drug-related
patterns. Furthermore, the fact that the patterns of the
older participants were made up of more than one
anatomical system was possibly related to the burden of
chronic disease associated with age [23]. The observed
medication patterns should coincide with the multimor-
bidity ones given that the former reflect the various ill-
nesses being treated. For instance, if we compare
multimorbidity and medication patterns from the same
sample, the endocrine-metabolic multimorbidity pattern
should be related to the alimentary tract and metabol-
ism one [35]. A concept that concurs with a number of
publications that have reported that medication data
may represent a way of identifying chronic conditions
[47]. Following this idea, medication patterns could help
characterise individuals with multimorbidity. Finally, the
use of three criteria to define patterns permitted a repre-
sentation of all drugs, including those related to low
prevalence diseases. Variability between chronic diseases
and treatments was thus respected in our results.
To the best of our knowledge, only one study has pre-
viously defined medication patterns using EFA [22], and
few authors have investigated such patterns in patients
with multimorbidity [16]. It is difficult to draw compari-
sons because of differences in drug inclusion criteria,
number of drugs considered, and especially method-
ology. Nevertheless, some anatomical systems, including
cardiovascular, respiratory, and neurological ones were
the same. Such similarities are probably related to the
strong prevalence of chronic conditions. Nevertheless,
with CA we obtained 6 markedly different patterns, and
with the O/E ratio and the exclusivity criteria we could
define which drugs were over-represented, playing a
more crucial role.
A recent publication has established that guidelines
addressing polymedication appear arbitrary [15]. Our re-
search thus contributes to the definition of medication
patterns which could be used to identify both user pro-
files and safety issues (e.g. detecting prescription errors,
for instance inappropriate drugs, or drug-drug associa-
tions), something that is not possible with multimorbid-
ity patterns. The definition of medication patterns could
open new paths to create instruments to prioritize
groups of individuals and permit effective prescription.
In addition, establishing medication patterns in accord-
ance to multimorbidity patterns would help to deter-
mine prognostic factors in drug safety, define possible
adverse drug reactions, and identify drug-drug and drug-
disease interactions. The analysis of medication patterns
thus provides an additional perspective for interpreting
and defining the population’s health.
Strength and weakness
Our study sample is both reliable and representative of the
population, thus adding robustness to our results. Moreover,
we provide an accurate reflection of real prescribing habits
for the elderly with multimorbidity in an urban public
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primary health care setting. Analyses of individual medica-
tion patterns can lead to new insights into individual pre-
scription situations. We consider that complexity among
patients is well represented in these patterns. However, some
limitations should be considered. On one hand, selected cri-
teria of chronicity (prescription of 6 or more months) may
have caused a selection bias, although we followed an estab-
lished definition [23]. In addition, we have to assume that
CA is inherently exploratory in nature and different cluster-
ing algorithms may produce varying results. The lack of
studies defining medication patterns also limits comparisons
between results and populations. Finally, we should consider
as a limitation the fact that the collected data were 10 years
old and may not exactly reflect current prescription patterns.
Nevertheless, these medication patterns correspond to a six-
year longitudinal multimorbidity study [35, 48] in which it
was observed that multimorbidity patterns did not differ at
all during the period studied. In addition, in public primary
health care, the implementation of new treatments for spe-
cific diseases (for example, oral anticoagulants or oral antidi-
abetic medications) are not yet generalised. For this reason,
we considered that the medication patterns represented
current prescription.
Future research
Medication patterns could change with time as a conse-
quence of multimorbidity evolution and new treatments
applied in some chronic diseases. Our study is cross-
sectional, but in future research it would be advantageous
to analyse large prospective cohorts with different esti-
mates to define medication patterns and identify their sta-
bility or evolution. In addition, generational differences
are expected due to modified lifestyle habits. Thus, re-
analyses should be considered as medication patterns are
expected to alter across decades.
Taking into account drug prescription and medication
patterns, improvements in guidelines for the clinical man-
agement of elderly patients should be contemplated. In
addition, the methodology used for clustering could be a
starting point for analysing drug safety in relation to drug
interaction.
Conclusions
This study provides information about prescription drugs
in an urban population of older adults with multimorbid-
ity. Our results showed highly elevated prescription rates,
particularly in the older subset of patients, probably due
to the greater burden of chronic disease. Clinical practice
should consider reviewing off-label prescribed drugs for
possible de-prescription.
The study of medication patterns provides a method for
analysing the use of multiple drugs in elderly patients. We
identified 6 medication patterns in our series which could
provide new avenues for evaluating multimorbidity.
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